Introduction
============

Imbalance in the production of adipocytokines (adipokines) from adipose tissue is involved in various pathological states, such as metabolic syndrome, hyperlipidemia, hypertension, atherosclerosis and diabetes mellitus, among others ([@r1]-[@r3]). Adipokines determine adipose tissue function, fat distribution, fat mass, liver function, insulin sensitivity; and importantly, visceral fat accumulation also has an impact on adipokine secretion profile ([@r4]). In addition, adipose tissue *via* adipokines plays an important role in the regulation of immune response and systemic inflammation. In this view, action of adipokines is either pro-inflammatory (e.g., leptin, resistin, interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α)), or anti-inflammatory (e.g., adiponectin) ([@r5]).

It remains a challenge to identify asymptomatic individuals who are at an increased risk of developing metabolic syndrome. Serum bilirubin is a strong endogenous antioxidant with anti-inflammatory properties ([@r6], [@r7]). Several epidemiological and large-scale population studies have shown that higher serum bilirubin levels protect against the development of diabetes mellitus, hypertension, coronary artery disease, stroke, and cardiovascular diseases (CVD) ([@r7]-[@r12]). Serum bilirubin levels were also inversely correlated with the prevalence of metabolic syndrome, which is considered as a pre-diabetes state ([@r9], [@r10]). Moreover, bilirubin has been recently speculated as a potential pre-disease biomarker for the development of metabolic syndrome in asymptomatic middle-aged individuals ([@r13]). In this perspective, bilirubin can be considered as surrogate endpoint for cardiovascular or metabolic diseases, especially if measured longitudinally over time in single patient to reflect positive or negative changes due to lifestyle modification or therapeutic approaches. This consistent pathophysiological evidence combined with the epidemiological data opens up the perspective for bilirubin to be used as a biomarker for therapeutic interventions.

Overweight and obese individuals have increased serum levels of pro-inflammatory adipokines such as leptin, TNF-α, IL-6, resistin, and visfatin ([@r14]). Interestingly, resistin that is released within fat tissue acts on adipocytes directly, thus leading to insulin resistance independently of body mass index (BMI) ([@r15]). In contrast to other adipokines, serum levels of adiponectin decrease in obese subjects ([@r16]). Furthermore, hypoadiponectinemia is associated with visceral fat accumulation, and is also closely linked to higher waist circumference, blood pressure, fasting insulin, insulin resistance index, total cholesterol, low density lipoprotein (LDL) cholesterol, very low density lipoprotein (VLDL) cholesterol, and triacylglycerols ([@r17], [@r18]). Accordingly, decreased serum levels of adiponectin are considered as a new hypothesis to explain the pathophysiology of metabolic syndrome ([@r19]).

Here we proposed the idea that serum adipokines and serum bilirubin might have direct correlation already in the asymptomatic individuals, i.e. in the early pre-disease states. The proof of this concept could open the perspective of using longitudinal screening of serum bilirubin values as a biomarker for cardiovascular and metabolic pre-disease states, in which reversible changes with lifestyle modification are still possible. Up to date, the role of adipokines in respect to bilirubin is described in the literature mainly in studies dealing with hepatic diseases. On the other hand, induction of bilirubin synthetic enzyme heme oxygenase-1 (HO-1) in adipocytes improved adipocyte function and adipose remodeling by increasing adiponectin levels ([@r20]).

In a recent clinical study, serum bilirubin was positively correlated to adiponectin ([@r21]). Therefore, the aim of our study was to elucidate the relationship between serum adipokines and serum bilirubin levels in asymptomatic normal weight and overweight individuals.

Materials and Methods
=====================

Study population
----------------

In this cross-sectional study, 96 apparently healthy participants of Caucasian origin were included. Participants were recruited by internet and media advertisement and selected by the following exclusion criteria: (i) having 19≥BMI≥35; (ii) having drug therapy for lipid disorders, or taking non-steroidal anti-inflammatory drugs (NSAIDs); (iii) having any cardiovascular, endocrine, acute or chronic inflammatory disease, including diabetes mellitus type 2; (iv) being a smoker; and (v) not completing the questionnaires, or not reporting stable weight over the last three months (loss or gain \<3% of the subject's weight was tolerated). All volunteers were fully informed on the study procedures, and written informed consent was obtained from each subject upon enrolment. The study was conducted with approval from the Slovenian National Medical Ethics Committee (No. 56/08/11 bis), and the experimental protocol was in accordance with the Declaration of Helsinki from 2004.

Measurement of body composition
-------------------------------

Subject anthropometric measures, including height, weight, waist and hip circumference were performed by the protocol previously described ([@r13]). All participants were subjected to the following measurements: (i) body weight was recorded to the nearest 0.1 kg, and height to the nearest 0.1 cm in standing position using a Leicester Height Measure (Invicta Plastics Limited, Oadby, England); (ii) waist circumference was measured midway between the costal edge and iliac crest; (iii) calculating BMI; and (iv) body composition analyses (total percentage of body fat (% BF) and trunk fat (% TF)) were performed using a body composition analyzer (BIA) Tanita BC 418MA (Tanita Corporation, Arlington Heights, IL, USA). Overweight group consisted of all participants that had at least two of three following characteristics: (i) BMI ≥25 kg/m^2^; (ii) visceral obesity -- waist circumference (≥94 cm (men) and ≥80 cm (women); and (iii) % of total fat (≥21.5% (men) and ≥32% (women).

Serum measurements
------------------

After overnight fast, whole blood samples for different biochemical analyses were collected in the morning into red topped tubes (Becton-Dickinson, Rutherford, USA). After whole blood collection, the blood was left at room temperature for 20 minutes. Then, the clot was removed immediately by centrifugation; the resulting supernatant was transferred into a clean polypropylene tube frozen and stored at -20 °C until analysis.

Cytokines, including IL-6 and TNF-α, but also adipokine visfatin were measured in serum, as previously described ([@r22]). Briefly, serum levels of visfatin, IL-6, TNF-α and adiponectin were determined in duplicate on a microplate reader (Tecan, Männedorf, Switzerland) using human ELISA kit for visfatin (BioVision, Mountain View, CA, USA), IL-6 and TNF-α (Thermo Fischer Scientific Inc., Rockford, USA), and adiponectin and resistin (BioVendor, Laboratory Medicine Inc., Brno, Czech Republic). Assay sensitivity was 26 ng/mL for adiponectin and 33 pg/mL for resistin, whereas inter-assay and intra-assay coefficient of variation (CV) was \<10% both. In addition, serum concentrations of different biochemical parameters were analyzed using standard techniques, as previously reported ([@r13]). To sum up, using Olympus reagents, serum concentrations of total and direct bilirubin, standard serum blood lipids, including total cholesterol, LDL cholesterol, HDL cholesterol and triacylglycerols but also serum glucose and CRP were measured on an AU 680 analyzer (Beckman Coulter, Pasadena, CA, USA). In addition, serum insulin levels were analyzed on an Abbott Architect 2000 iSR analyzer (Abbott Diagnostics, Abbot Park, IL, USA).

Statistics
----------

Descriptive statistics was used to analyze data distribution and to summarize the data. Non normally distributed data (concentrations of bilirubin, adiponectin, visfatin, TNF-α, LDL cholesterol, triacylglycerols, CRP, and insulin) were logarithmically transformed to approximate normal distribution. In general, data were expressed as mean ± SD unless otherwise stated. To analyze the effect of obesity measures on serum bilirubin, adipokines and inflammatory markers, subjects were divided according to obesity measures (body fat, BMI, and waist circumference). Independent Student's t-test was used to compare the two groups. Spearman's correlation analyses were used to detect relationships between fasting serum concentrations of bilirubin and adipokines or inflammatory markers before and after BMI adjustment. Step by step regression analysis was used to explore the predictors of fasting serum concentrations of total bilirubin (dependent variable). Independent variables were adipokines and cytokines. Moreover, hierarchical multiple regression analysis was performed to examine the effects of studied adipokines on serum bilirubin levels. First, general parameters (age and gender) were entered as control variables (step 1), followed by indicators of obesity (waist to hip ratio and body fat mass) (step 2). Then, some other possible confounders such as fasting glucose, insulin, triacylglycerols and total cholesterol were entered (step 3), followed by adipokines and inflammatory markers (step 4). For all statistical analyses, the IBM SPSS version 19.0 (SPSS Inc., Chicago, IL, USA) was used. The level of statistically significant difference between the tested parameters was set at p\<0.05.

Results
=======

Baseline anthropometric and biochemical characteristics
-------------------------------------------------------

Some of the previously described anthropometric and biochemical data on the two study groups, i.e. normal weight (16 male and 32 female participants) and overweight (16 male and 32 female participants) are shown in [Tables 1 and 2](#t1){ref-type="table"}[](#t2){ref-type="table"}. Participants in the two groups differed in all obesity measures, including BMI, waist to hip ratio, % BF, and % TF. The metabolic profile of cytokines and adipokines of the two study groups is shown in [Table 2](#t2){ref-type="table"}. Subjects in the overweight group had significantly higher levels of fasting insulin, blood lipids, including triacylglycerols, total cholesterol and LDL cholesterol, and lower levels of HDL cholesterol and total bilirubin as compared with the normal weight group. In the overweight group, circulating levels of CRP, IL-6, visfatin, and TNF-α were higher, while adiponectin levels were lower.

###### Anthropometric and biochemical parameters of normal weight and overweight groups, previously published by Jenko-Pražnikar et al. ([@r13])

                               Normal weight subjects   Overweight subjects   p value
  ---------------------------- ------------------------ --------------------- ---------
  Number of participants       48                       48                    NS
  Gender (M/F)                 16/32 (33%/67%)          16/32 (33%/67%)       NS
  Age (years)                  37±6                     39±6                  NS
  BMI (kg/m^2^)                21.9±2.4                 29.4±2.7              \<0.001
  Waist to hip ratio           0.82±0.07                0.88±0.09             \<0.001
  Body fat (%)                 21±6                     34±8                  \<0.001
  Trunk fat (%)                19±6                     33±6                  \<0.001
  Fasting glucose (mmol/L)     5.0±0.4                  5.2±0.4               NS
  Fasting insulin (unit)       5.4±1.7                  9.2±4.3               \<0.001
  Triacylglycerols (mmol/L)    0.94±0.50                1.38±0.74             \<0.001
  Total cholesterol (mmol/L)   5.0±0.9                  5.6±1.1               0.011
  HDL cholesterol (mmol/L)     1.5±0.3                  1.3±0.3               0.001
  LDL cholesterol (mmol/L)     3.1±0.7                  3.6±1.0               0.004
  CRP (mg/L)                   0.84±0.86                3.02±3.06             \<0.001
  Bilirubin-total (µmol/L)     15.4±3.1                 13.2±2.8              0.042
  Bilirubin-direct (µmol/L)    2.5±0.6                  2.1±0.6               0.038

All values are mean ± SD; M = male; F = female; BMI = body mass index; HDL = high-density lipoprotein; LDL = low-density lipoprotein; CRP = C-reactive protein; NS = nonsignificant.

Comparisons of biochemical and other characteristics between the two groups were completed with the use of one-factor analysis of variance with Bonferroni correction. The mean difference was significant at the 0.05 level.

###### Adipokine levels in normal weight and overweight subjects

  ---------------------------------------------------------------------------------
                           Normal weight subjects   Overweight subjects   p value
  ------------------------ ------------------------ --------------------- ---------
  Number of participants   48                       48                    NS

  TNF-α\                   2.0±1.6                  5.2±3.3               \<0.001
  (pg/mL)                                                                 

  IL-6\                    2.8±1.0                  3.2±0.9               0.021
  (pg/mL)                                                                 

  Adiponectin (µg/mL)      7.0±3.8                  4.6±2.7               0.009

  Resistin\                8.0±2.5                  8.2±2.6               ns
  (µg/mL)                                                                 

  Visfatin\                2.0±0.6                  4.2±0.9               0.002
  (ng/mL)                                                                 
  ---------------------------------------------------------------------------------

All values are mean ± SD; IL-6 = interleukin 6; TNF-α = tumor necrosis factor alpha; NS = nonsignificant.

Comparisons of biochemical and other characteristics between the two groups were completed with the use of one-factor analysis of variance with Bonferroni correction. The mean difference was significant at the 0.05 level.

Correlation between serum adipokines and bilirubin levels
---------------------------------------------------------

Bilirubin is present in serum in conjugated (direct bilirubin) and unconjugated (indirect bilirubin) forms. The sum of both forms results in total bilirubin. Serum bilirubin levels, i.e. total and direct bilirubin, were higher in the normal weight participants in comparison to the overweight participants. Both forms of bilirubin correlated in the same manner with the increasing number of metabolic syndrome parameters, as published previously ([@r13]). Associations of total serum bilirubin with both serum adipokines and pro-inflammatory cytokines are shown in [Table 3](#t3){ref-type="table"} and [Figure 1](#f1){ref-type="fig"}. We detected a significant negative association between total bilirubin and CRP, TNF-α, visfatin and resistin values, and a significant positive association between total serum bilirubin and adiponectin values (p\<0.05 all) ([Table 3](#t3){ref-type="table"}), before stratifying subjects on the basis of BMI. Importantly, after BMI adjustment, we found a significant negative association between total serum bilirubin levels and both visfatin (-0.29; p=0.034) and CRP (-0.33; p=0.001) serum levels. Due to the known relationship between BMI and bilirubin levels, both associations were less strong, but still statistically significant.

###### Spearman correlation coefficients of fasting serum levels of total bilirubin with adipokines and after adjustment for BMI

  Independent variable   Total bilirubin   Total bilirubin after adjustment for BMI           
  ---------------------- ----------------- ------------------------------------------ ------- -------
                         r                 p                                          r       p
  CRP                    -0.33             0.001                                      -0.33   0.001
  TNF-α                  -0.29             0.018                                      -0.17   0.251
  Visfatin               -0.31             0.021                                      -0.29   0.034
  Adiponectin            0.24              0.024                                      0.14    0.321
  Resistin               -0.25             0.019                                      -0.24   0.059
  IL-6                   0.14              0.151                                      0.10    0.434

BMI = body mass index; CRP = C-reactive protein; IL-6 = interleukin 6; TNF-α = tumor necrosis factor alpha

![Correlations between total serum bilirubin levels and serum cytokines and adipokines levels. (A) Serum adiponectin; (B) serum visfatin; (C) C-reactive protein (CRP); (D) serum interleukin-6 (IL-6); (E) serum tumor necrosis factor alpha (TNF-alpha); (F) serum resistin. Results are presented for male (0) and female (1) participants (circles and squares). Pearson's correlation analysis was performed (N=96).](acc-59-19-f1){#f1}

Moreover, [Table 4](#t4){ref-type="table"} shows the results of linear regression analysis between the level of the dependent variable of serum bilirubin (total and direct) and CRP, TNF-α, visfatin, resistin, adiponectin and IL-6. All associations except for resistin were stronger and more significant in males than in females.

###### Results of linear regression analysis (by gender) between serum bilirubin (total and direct) level and other variables

  Independent variable   Total bilirubin   Direct bilirubin                 
  ---------------------- ----------------- ------------------ ------------- ----------------
                         r (M/F)           p (M/F)            r (M/F)       p (M/F)
  CRP                    -0.71/-0.28       \<0.0001/0.047     -0.62/-0.31   \<0.0001/0.046
  TNF-α                  -0.30/-0.25       0.016/0.032        -0.24/-0.23   0.047/0.048
  IL-6                   0.28/-0.13        0.131/0.323        0.26/-0.11    0.157/0.420
  Adiponectin            0.33/0.23         0.011/0.029        0.36/0.25     0.010/0.021
  Visfatin               -0.42/-0.31       0.012/0.018        -0.30/-0.29   0.019/0.023
  Resistin               -0.15/-0.37       0.167/0.004        -0.13/-0.28   0.276/0.032

M = male; F = female; CRP = C-reactive protein; IL-6 = interleukin 6; TNF-α = tumor necrosis factor alpha

Adipokines as predictors of serum bilirubin level
-------------------------------------------------

Results of multiple stepwise regression analyses with serum bilirubin (total) as a dependent variable in male and female subjects are presented in [Table 5](#t5){ref-type="table"}. Visfatin was strong and gender nonspecific predictor of serum bilirubin. Furthermore, CRP was predictor of serum bilirubin in male individuals, and resistin in female subjects.

###### Results of multiple stepwise regression analysis with serum bilirubin (total) as a dependent variable in male and female subjects

  Independent variable   Male    Female           
  ---------------------- ------- -------- ------- -------
  β                      p       β        p       
  CRP                    -0.53   0.020    -0.22   NS
  TNF-α                  -0.15   ns       -0.14   NS
  IL-6                   0.13    ns       -0.08   NS
  Adiponectin            0.21    ns       0.22    NS
  Visfatin               -0.46   0.006    -0.28   0.039
  Resistin               -0.04   ns       -0.35   0.020

CRP = C-reactive protein; IL-6 = interleukin 6; TNF-α = tumor necrosis factor alpha; NS = nonsignificant

Variables included in the model were CRP, TNF-α, IL-6, adiponectin, resistin and visfatin. Only significant p values are shown in multivariate analysis (p\<0.05).

To further examine the effects of adipokines on serum bilirubin level, we also performed hierarchical multiple regression analysis, as shown in [Table 6](#t6){ref-type="table"}. The hierarchical multiple regression revealed that at stage one, general parameters, e.g., age and gender, contributed to the regression model and accounted for 13% of the variation in serum levels of bilirubin. Introducing obesity parameters in stage two of the regression model (e.g., waist to hip ratio and body fat mass) explained additional 4% of the variation in serum level of bilirubin. In addition, the results of the regression in step 3 indicated that four predictors (fasting glucose, insulin, triacylglycerols and total cholesterol) explained an additional 24% of the variation in serum level of bilirubin, and change in *R^2^* was significant (p\<0.01). Step 4 was also significant with adipokines and CRP as important predictors of serum bilirubin level (visfatin and CRP significantly contributed to the explained variation of serum bilirubin level) and explained 11% of the variation of serum bilirubin level. It was found that the level of serum bilirubin was significantly predicted by body fat mass (β=-0.436, p\<0.05), slightly more as did fasting insulin (β=-0.415, p\<0.01), visfatin (β=-0.321, p\<0.05), serum triacylglycerols (β=-0.301, p\<0.05) and CRP (β=-0.284, p\<0.05). Together, the adjusted *R^2^* value was 0.52. This indicated that 52% of the variance in serum level of bilirubin was explained by the proposed model.

###### Results of hierarchical multiple regression analysis for variables predicting serum bilirubin levels^\#^

                         Dependent variable -- bilirubin          
  ---------------------- --------------------------------- ------ ----------
  Predictor              β                                 *F*    Δ*R*^2^
  Step 1:                                                  4.40   0.13\*
    Age                  -0.243                                   
    Gender               -0.216                                   
  Step 2:                                                  2.82   0.04\*
    Waist to hip ratio   -0.203                                   
    Body fat mass        -0.436\*                                 
  Step 3:                                                  4.47   0.24\*\*
    Fasting glucose      -0.123                                   
    Fasting insulin      -0.415\*\*                               
    Triacylglycerols     -0.301\*                                 
    Total cholesterol    -0.176                                   
  Step 4:                                                  4.01   0.11\*\*
    CRP                  -0.284\*                                 
    Visfatin             -0.321\*                                 
    Resistin             -0.145                                   
    Adiponectin          0.189                                    
    IL-6                 0.165                                    
    TNF-α                -0.197                                   
  Total *R*^2^                                                    0.52\*\*
  N                                                               96

***^\#^*** BMI = body mass index; CRP = C-reactive protein; IL-6 = interleukin 6; TNF-α = tumor necrosis factor alpha; \*p\<0.05, and \*\*p\<0.01.

Discussion
==========

In this study, we demonstrated for the first time that total serum bilirubin levels in overweight and normal weight middle-aged asymptomatic subjects were negatively associated with some proinflammatory adipokines, such as visfatin and resistin, and inflammatory cytokines such as TNF-α, IL-6 and CRP, whereas serum bilirubin was positively associated with anti-inflammatory adiponectin. Moreover, serum levels of CRP, visfatin, and resistin were strong predictors of serum bilirubin levels.

Bilirubin in normal concentration is a potent endogenous antioxidant and anti-inflammatory agent in serum, which can neutralize free radicals, prevent peroxidation of lipids, and decrease oxidative stress ([@r23]). Indeed, in our study, we observed an inverse relationship between serum bilirubin levels and pro-inflammatory cytokines (TNF-α, IL-6) and CRP, thereby confirming the anti-inflammatory activity of bilirubin, as previously described ([@r24]). Our data are in agreement with other studies, describing that total bilirubin was inversely correlated with CRP in overweight subjects ([@r8], [@r12], [@r25]). In addition, in our study, CRP level was a predictor of serum bilirubin in male individuals. On the other hand, weight loss is associated with a rapid increase in total bilirubin levels and antioxidant capacity ([@r12], [@r25]).

We showed that adiponectin, which is an anti-inflammatory adipokine, was positively correlated with serum bilirubin levels in asymptomatic middle-aged individuals. Previously, positive correlation of adiponectin with serum bilirubin was described in non-diabetic men; however, in comparison to our study, those subjects were older, some were symptomatic (hypertension, microalbuminuria), and/or smokers, which all can affect serum bilirubin levels ([@r21]). Many other studies described this correlation in patients with liver cell injury, e.g., cirrhosis and cholestasis ([@r26]). It is important to notice that both serum bilirubin ([@r6]) and serum adiponectin ([@r5], [@r27]) have beneficial effects in a variety of CVD. Moreover, both show negative correlation with obesity and BMI ([@r5], [@r9]).

The physiology of bilirubin and adiponectin also combines in the heme oxygenase-adiponectin axis response. Heme oxygenase-1 system is involved in enhancing adiponectin synthesis and release ([@r28]). Pathologic conditions such as oxidative stress and inflammation up-regulate the level of inducible heme oxygenase (HO-1), thereby increasing total bilirubin levels ([@r29]). Overexpression of HO-1 resulted in a marked increase in adiponectin with a corresponding decrease in the levels of inflammatory cytokines TNF-α, IL-1β and IL-6 in animal models of obesity ([@r20], [@r30]). Indeed, we observed a correlation between TNF-α and serum bilirubin, but there was no correlation with IL-6. Moreover, HO-1 induction alters the physical appearance of adipocytes, i.e. from few large to many smaller adipocytes ([@r31]). These modified adipocytes led to increases in anti-inflammatory AMPK, PPARγ, and adiponectin, whereas on the other hand, they decreased the production of inflammatory cytokines such as TNF-α and IL-6 ([@r31]). Furthermore, HO-1 induction was found to be beneficial in obesity by inhibiting adipogenesis, i.e. preventing the formation of adipose tissue from mesenchymal stem cells ([@r32]). Indeed, diabetic patients have reduced HO-1 responses to chronic inflammation and oxidative stress, and thus consequently lower serum bilirubin and adiponectin levels ([@r33]).

Herewith we report for the first time a strong negative association between serum visfatin and bilirubin levels. In addition, we found higher serum visfatin levels in overweight subjects in comparison to the normal weight ones, which is in agreement with previous studies ([@r22], [@r34]). Increased serum visfatin levels are associated with the obesity-related morbidities ([@r35]), higher presence of coronary artery disease ([@r36]), and higher risk of acute myocardial infarction ([@r37]). Visfatin was positively associated with insulin resistance, and thus suggested as a biomarker for predicting obesity, diabetes status, insulin resistance, metabolic syndrome and CVDs ([@r34]). In previous studies, increased visfatin levels and increased bilirubin levels have been reported in patients with liver diseases, e.g., chronic viral hepatitis ([@r38]). Indeed, obese individuals with healthy liver function can have increased visfatin levels similar to the patients with non-alcoholic fatty liver disease ([@r39]). Thus, negative correlation between serum bilirubin and visfatin applies only to the individuals with no liver disease.

A major limitation of our cross-sectional study was a small number of subjects enrolled. Thus, a prospective study involving a larger number of subjects is necessary to confirm the correlation between serum bilirubin and studied adipokines, and to further investigate low serum bilirubin levels as a cardiovascular risk factor in overweight subjects. Secondly, our study assumed that total bilirubin levels correlated with free bilirubin, which is the unconjugated and unbound bilirubin ([@r40]). It is the bioactive form, but it is not routinely measured in clinical settings; however, in healthy adults, its concentration is around 10 nM ([@r41]). To better elucidate the bilirubin mechanisms of actions on adipocytes, free bilirubin values should be employed in future studies.

There is only scarce evidence for bilirubin effects on adipocytes. However, bilirubin can act as: (i) direct radical scavenger of reactive oxygen species (ROS) and nitrogen species since reduced oxidative stress in adipocytes decreases the activation of the intracellular ASK1-MEK4-JNK signaling pathway that is crucial in insulin resistance ([@r42]); (ii) inhibitor of NAPDH oxidase, which is the most important source of intracellular adipocyte ROS production ([@r42]); and (iii) activator of peroxisome-proliferator-activated receptor α (PPARa) ([@r43]). Another possible explanation could be the anti-inflammatory effects of bilirubin on activated macrophages in hypertrophic visceral adipose tissue, which also express high levels of NADPH oxidase ([@r44]).

Overall, serum bilirubin has been previously shown to be decreased in asymptomatic individuals before the onset of metabolic syndrome, on the basis of correlation with body weight, fat level, insulin resistance, LDL, HDL, triacylglycerols, CRP and physical activity. Here we further support this view by presenting that altered adipokine levels decrease in anti-inflammatory adiponectin and increase in pro-inflammatory visfatin are also correlated with lower serum bilirubin levels. Importantly, this study was conducted in asymptomatic, non-smoking, middle-aged individuals with stable body weight, who are the key population for CVD prevention. This study opens the perspective of measuring adipose tissue dysfunction by serum biomarkers such as adipokines and bilirubin, and studying their role in the early pathogenesis of metabolic syndrome.
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